CureVac COVID-19 vaccine hits just 48% efficacy in final analysis

German biotech company CureVac announced its COVID-19 vaccine demonstrated 48% efficacy against COVID-19 of any severity in a final readout of late-stage trial data. The results reflect a slight increase over preliminary data suggesting 47% efficacy during the company’s readout earlier this

CureVac Covid-19 Vaccine 48% Effective in Pivotal Study

German company CureVac NV released the final results for its once-promising Covid-19 vaccine, finding it provided less protection than the vaccines already authorized for use in the U.S. The company said Wednesday that its vaccine was 48% effective in providing protection against

Germany’s CureVac COVID-19 vaccine flops in clinical trial

German biopharmaceutical company CureVac’s COVID-19 mRNA vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking. “In the unprecedented context of at least 13 variants

Germany’s CureVac COVID-19 vaccine flops in clinical trial

German biopharmaceutical company CureVac’s COVID-19 mRNA vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking. “In the unprecedented context of at least 13 variants

CureVac Covid-19 Vaccine Candidate Disappoints in Key Study

CureVac CVAC -3.47% NV said Wednesday its experimental Covid-19 vaccine was 47% effective against the disease in an interim analysis of a large clinical trial, a disappointing outcome likely to dim the shot’s prospects for wider use. The setback could hinder vaccination